NIKKEI 225
38,179.18 -49.93 (-0.13%) HANG SENG
18,935.83 -27.85 (-0.15%) CRUDE OIL
77.97 -0.29 (-0.37%) GOLD FUTURES
2,365.50 -9.50 (-0.40%) DOW
39,512.84 +837.14 (+2.16%) Bitcoin GBP
48,819.18 +214.55 (+0.44%)
OLMA May 2024 15.000 call
| Previous close | 0.3100 |
| Open | 0.3100 |
| Bid | 0.0000 |
| Ask | 0.6000 |
| Strike | 15.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.3100 - 0.3100 |
| Contract range | N/A |
| Volume | |
| Open interest | 12 |
GlobeNewswireOlema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
Completed enrollment in 60-patient Phase 1b/2 clinical studies of palazestrant in combination with each of ribociclib and palbociclibNew clinical data from palazestrant-ribociclib combination study to be presented at the ESMO Breast Cancer Annual Congress 2024 in Berlin, Germany. Olema will host an investor conference call on May 15, 2024, at 8:00 a.m. ET to review the dataInvestigational New Drug (IND) application for OP-3136, a novel KAT6 inhibitor, expected to be filed with FDA in late 2024Ca
- GlobeNewswire
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
Olema will host an investor conference call at 8:00 a.m. ET on May 15, 2024SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that it will present new clinical data from the Company’s ongoing Phase 1b/2 clinical study of palazestrant in combination with CDK4/6 inhibit
- GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company granted stock options to six new employees to purchase an aggregate of 187,400 shares of the Company's common stock, effective as of May 1, 2024. These awards were approved by the Compensation Commit
